BioCentury
ARTICLE | Finance

Takeda gets Ambys-tious

Takeda finally gets the ball rolling in liver diseases with $140M Ambys deal

August 10, 2018 11:08 PM UTC

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area of gastroenterology.

The way it solved the problem was by taking its trend of doing earlier and earlier deals to its logical conclusion -- company formation...